Page last updated: 2024-11-11
balaglitazone
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
balaglitazone: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 9889200 |
| CHEMBL ID | 2103991 |
| SCHEMBL ID | 242011 |
| MeSH ID | M0481676 |
Synonyms (44)
| Synonym |
|---|
| nnc-61-2344 |
| nn-2344 |
| nnc-61-0645 |
| balaglitazone |
| drf-2593 |
| nn 2344 |
| 5-(p-((3,4-dihydro-3-methyl-4-oxo-2-quinazolinyl)methoxy)benzyl)-2,4-thiazolidinedione |
| drf 2593 |
| nn2344 |
| 4m1609828o , |
| balaglitazone [inn] |
| unii-4m1609828o |
| 199113-98-9 |
| (+-)-5-(p-((3,4-dihydro-3-methyl-4-oxo-2-quinazolinyl)methoxy)benzyl)-2,4-thiazolidinedione |
| CHEMBL2103991 |
| SCHEMBL242011 |
| CS-1441 |
| HY-16086 |
| IETKPTYAGKZLKY-UHFFFAOYSA-N |
| 5-[4-[[3-methyl-4-oxo-3,4-dihydroquinazolin-2-yl]methoxy]benzyl]thiazolidine-2,4-dione |
| 5-[4-[[-methyl-4-oxo-3,4-dihydroquinazolin-2-yl]methoxy]benzyl]thiazolidine-2,4-dione |
| 5-((4-((3-methyl-4-oxo-3,4-dihydro-2-quinazolinyl)methoxy)phenyl)methyl)thiazolidine-2,4-dione |
| (+/-)-5-(p-((3,4-dihydro-3-methyl-4-oxo-2-quinazolinyl)methoxy)benzyl)-2,4-thiazolidinedione |
| balaglitazone [who-dd] |
| 2,4-thiazolidinedione, 5-((4-((3,4-dihydro-3-methyl-4-oxo-2-quinazolinyl)methoxy)phenyl)methyl)- |
| AKOS030526698 |
| 5-({4-[(3-methyl-4-oxo-3,4-dihydroquinazolin-2-yl)methoxy]phenyl}methyl)-1,3-thiazolidine-2,4-dione |
| AS-74629 |
| 5-(4-((3-methyl-4-oxo-3,4-dihydroquinazolin-2-yl)methoxy)benzyl)thiazolidine-2,4-dione |
| A856108 |
| DB12781 |
| FT-0766930 |
| BCP11371 |
| SB16864 |
| drf 2593;nn 2344 |
| drf-2593;nn-2344;nnc-610645 |
| 2,4-thiazolidinedione, 5-[[4-[(3,4-dihydro-3-methyl-4-oxo-2-quinazolinyl)methoxy]phenyl]methyl]- |
| Q27260063 |
| F84947 |
| 5-[[4-[(3-methyl-4-oxoquinazolin-2-yl)methoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione |
| ZHA11398 |
| EX-A3756 |
| 2,4-thiazolidinedione,5-[[4-[(3,4-dihydro-3-methyl-4-oxo-2-quinazolinyl) methoxy]phenyl]methyl]- |
| DTXSID30870213 |
Research Excerpts
Overview
Balaglitazone (DRF-2593) is a novel partial agonist of PPAR-gamma (γ) It is in clinical development for the treatment of type 2 diabetes.
Treatment
| Excerpt | Reference | Relevance |
|---|---|---|
| "Balaglitazone treated groups shown significantly reduce of HbA1c (%), FSG (mmol/L), postprandial glucose as comparison to pioglitazone." | ( Balaglitazone: a second generation peroxisome proliferator-activated receptor (PPAR) gamma (γ) agonist. Agrawal, R; Dikshit, SN; Jain, P, 2012) | 2.54 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Research
Studies (8)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (37.50) | 29.6817 |
| 2010's | 5 (62.50) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 25.51
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (25.51) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 3 (37.50%) | 5.53% |
| Reviews | 1 (12.50%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 4 (50.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||